Work

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7010

Authors: Joel W. Neal, Nathan A. Pennell, Ramaswamy Govindan, Michael Lanuti, Rachel Pam Greenerger Rosovsky, Rebecca Suk Heist, Alice Tsang Shaw, Jennifer S. Temel, Alona Muzikansky, Pasi A. Janne, Thomas James Lynch, Christopher G. Azzoli, Lecia V. Sequist

Institutions: Stanford University, Cleveland Clinic, Washington University in St. Louis, Massachusetts General Hospital, Dana-Farber Cancer Institute, Yale Cancer Center, Yale University, Smilow Cancer Hospital, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2195044552

Cites:

Cited by: 28

Related to: 10